NBP Stock Analysis: Buy, Sell, or Hold?
$0.91
-0.10 (-10.09%)
▼
5d:
-24.95%
30d:
-33.72%
90d:
-48.11%
WAIT
LOW Confidence
Analysis Updated: Nov 5, 2026 12:00 AM ET
Earnings: Sep 30, 2026
0d
Get Alerted When NBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NBP is down 25.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NBP is down 25.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NBP is currently trading at $0.91, which is considered oversold relative to its 30-day fair value range of $1.15 to $1.40.
Technical Outlook: Technically, NBP is in a downtrend. The price is currently testing key support at $0.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.1% recently.
Market Sentiment: NBP scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.67 (+854.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NBP is in a downtrend. The price is currently testing key support at $0.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.1% recently.
Market Sentiment: NBP scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.67 (+854.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.15 -
$1.40
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.1%)
- BULLISH: Trading 854.4% below Wall St target ($8.67)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.15 -
$1.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$1.39
Current Trend
Downtrend
Technical data as of
Nov 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.69
Wall Street Target
$8.67
(+854.4%)
Share & Embed Analysis
Last updated: November 06, 2026 6:28 AM ET
Data refreshes hourly during market hours. Next update: 7:28 AM
Data refreshes hourly during market hours. Next update: 7:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 47 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 43 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 61 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 44 HOLD |